New combo aims to boost transplant success in tough lymphoma

NCT ID NCT07451652

Recruiting now Disease control Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Source: ClinicalTrials.gov ↗

First seen Mar 06, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study tests whether a lower dose of the drug epcoritamab, combined with two chemotherapy drugs (gemcitabine and oxaliplatin), can shrink tumors in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The 10 participants must be eligible for a stem cell transplant. The goal is to see if this combination helps more people achieve remission before transplant, while reducing side effects like severe cytokine release syndrome.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Universitario "Dr. José Eleuterio González"
RECRUITING

Monterrey, Nuevo León, 64640, Mexico

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA